Skip to content
Latuda(lurasidone)
Latuda (lurasidone) is a small molecule pharmaceutical. Lurasidone was first approved as Latuda on 2010-10-28. It is used to treat bipolar disorder, major depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. The pharmaceutical is active against 5-hydroxytryptamine receptor 7. In addition, it is known to target alpha-2C adrenergic receptor, alpha-2A adrenergic receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
Latuda (generic drugs available since 2019-01-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lurasidone hydrochloride
Tradename
Company
Number
Date
Products
LATUDASunovion PharmaceuticalsN-200603 RX2010-10-28
5 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
latudaNew Drug Application2022-07-18
lurasidone hydrochlorideANDA2023-06-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bipolar disorderEFO_0000289D001714F30.9
major depressive disorderEFO_0003761D003865F22
schizophreniaEFO_0000692D012559F20
schizophrenia spectrum and other psychotic disorders—D019967—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Lurasidone Hydrochloride, Latuda, Sunovion Pharms Inc
92594232031-05-23U-1822
98272422031-05-23U-2199, U-2201
87290852026-05-26DP
88837942026-05-26DP
95550272026-05-26DPU-543
99077942026-05-26DP
RE455732025-06-23DP
91749752024-02-20U-1770
98158272024-02-20U-543, U-2166
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AE: Indole derivatives, antipsychotic
— N05AE05: Lurasidone
HCPCS
No data
Clinical
Clinical Trials
69 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F2066168238
Bipolar disorderD001714EFO_0000289F30.9—5142322
Psychotic disordersD011618F20.81—132—6
ManiaD000087122F30———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autistic disorderD001321EFO_0003758F84.0112——4
Suicidal ideationD059020EFO_0004320R45.851—32——3
Major depressive disorderD003865EFO_0003761F22——2—13
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Asperger syndromeD020817EFO_0003757F84.5—1———1
Pervasive child development disordersD002659EFO_0003756F84—1———1
Attempted suicideD013406EFO_0004321T14.91—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD0105992————2
Schizotypal personality disorderD012569F211————1
Healthy volunteers/patients—1————1
MetabolismD008660GO_00081521————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLURASIDONE
INNlurasidone
Description
Lurasidone is an N-arylpiperazine that is (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-(piperazin-1-ylmethyl)cyclohexyl]methyl}hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione in which position N4 of the piperazine ring is substituted by a 1,2-benzothiazol-3-yl group. Lurasidone is used (generally as the hydrochloride salt) as an atypical antipsychotic for the treatment of schizophrenia. It has a role as an adrenergic antagonist, a dopaminergic antagonist, a serotonergic antagonist and a second generation antipsychotic. It is a 1,2-benzisothiazole, a N-arylpiperazine, a bridged compound and a dicarboximide. It is functionally related to a maleimide. It is a conjugate base of a lurasidone(1+).
Classification
Small molecule
Drug classantipsychotic with binding activity on sertonin (5-HT2A) and dopamine (D2) receptors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1
Identifiers
PDB—
CAS-ID367514-87-2
RxCUI1040028
ChEMBL IDCHEMBL1237021
ChEBI ID70735
PubChem CID213046
DrugBankDB08815
UNII ID22IC88528T (ChemIDplus, GSRS)
Target
Agency Approved
HTR7
HTR7
Organism
Homo sapiens
Gene name
HTR7
Gene synonyms
NCBI Gene ID
3363
Protein name
5-hydroxytryptamine receptor 7
Protein synonyms
5-HT-7, 5-HT-X, 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled), Serotonin receptor 7
Uniprot ID
P34969
Mouse ortholog
Htr7 (15566)
5-hydroxytryptamine receptor 7 (Q14A50)
Alternate
ADRA2C
ADRA2C
ADRA2A
ADRA2A
DRD2
DRD2
HTR2A
HTR2A
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
ADRA2C
Gene synonyms
ADRA2L2, ADRA2RL2
NCBI Gene ID
152
Protein name
alpha-2C adrenergic receptor
Protein synonyms
adrenergic, alpha-2C-, receptor, Alpha-2 adrenergic receptor subtype C4, Alpha-2C adrenoceptor, Alpha-2C adrenoreceptor, Alpha-2CAR, alpha2-AR-C4
Uniprot ID
Q9HB49
Mouse ortholog
Adra2c (11553)
alpha-2C adrenergic receptor (Q01337)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,038 documents
View more details
Safety
Black-box Warning
Black-box warning for: Latuda, Lurasidone hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7,789 adverse events reported
View more details